Profile data is unavailable for this security.
About the company
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
- Revenue in USD (TTM)807.19k
- Net income in USD-6.59m
- Incorporated2007
- Employees2.00
- LocationAddex Therapeutics LtdChemin des Mines, 9PLAN-LES-OUATES 1202SwitzerlandCHE
- Phone+41 228841555
- Fax+41 228841556
- Websitehttps://www.addextherapeutics.com/en/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ibio Inc | 375.00k | -16.46m | 13.46m | 16.00 | -- | 0.7205 | -- | 35.88 | -1.81 | -2.34 | 0.0414 | 1.13 | 0.0108 | -- | -- | 23,437.50 | -47.53 | -27.69 | -77.58 | -33.13 | -- | -- | -4,389.33 | -1,862.11 | -- | -- | 0.0855 | -- | -- | -35.52 | 47.31 | -- | -26.66 | -- |
| Cell Source Inc | 0.00 | -6.57m | 13.52m | -- | -- | -- | -- | -- | -0.1613 | -0.1613 | 0.00 | -0.4379 | 0.00 | -- | -- | -- | -2,039.39 | -1,758.85 | -- | -- | -- | -- | -- | -- | -- | -3.74 | -- | -- | -- | -- | -3.55 | -- | -- | -- |
| Leap Therapeutics Inc | 0.00 | -69.40m | 13.67m | 52.00 | -- | 0.656 | -- | -- | -1.71 | -1.71 | 0.00 | 0.5029 | 0.00 | -- | -- | 0.00 | -149.01 | -79.03 | -202.35 | -93.29 | -- | -- | -- | -9,055.53 | -- | -- | 0.00 | -- | -- | -- | 16.74 | -- | -- | -- |
| Lyra Therapeutics Inc | 1.19m | -79.53m | 13.82m | 30.00 | -- | 2.94 | -- | 11.66 | -60.71 | -60.71 | 0.9039 | 2.94 | 0.012 | -- | -- | 39,500.00 | -80.40 | -64.59 | -94.88 | -76.36 | -- | -- | -6,711.39 | -5,844.58 | -- | -- | 0.00 | -- | -1.54 | -- | -49.07 | -- | 61.78 | -- |
| MetaVia Inc | 0.00 | -24.55m | 14.07m | 9.00 | -- | 1.42 | -- | -- | -3.27 | -3.27 | 0.00 | 0.5061 | 0.00 | -- | -- | 0.00 | -168.46 | -99.54 | -336.06 | -140.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -121.27 | -- | -48.18 | -- |
| Portage Biotech Inc | 0.00 | -67.28m | 14.10m | 7.00 | -- | 4.94 | -- | -- | -64.27 | -64.27 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -141.56 | -30.53 | -145.61 | -40.02 | -- | -- | -- | -- | -- | -- | 0.0387 | -- | -- | -- | 27.98 | -- | -- | -- |
| Synlogic Inc | 0.00 | 2.56m | 14.16m | 1.00 | 5.44 | 1.08 | 5.52 | -- | 0.2226 | 0.2226 | 0.00 | 1.12 | 0.00 | -- | -- | 0.00 | 9.49 | -44.41 | 13.42 | -50.06 | -- | -- | -- | -3,944.49 | -- | -- | 0.00 | -- | -99.76 | -67.55 | 61.88 | -- | -59.28 | -- |
| Bullfrog AI Holdings Inc | 0.00 | -7.14m | 14.22m | 9.00 | -- | 4.38 | -- | -- | -0.8102 | -0.8102 | 0.00 | 0.3448 | 0.00 | -- | -- | 0.00 | -121.13 | -- | -141.43 | -- | -- | -- | -- | -- | -- | -- | 0.0481 | -- | -100.00 | -- | -31.42 | -- | -- | -- |
| Addex Therapeutics Ltd - ADR | 807.19k | -6.59m | 14.25m | 2.00 | -- | 0.6947 | -- | 17.65 | -8.05 | 13.90 | 0.9852 | 12.71 | 0.1003 | -- | 4.94 | 403,597.40 | -81.90 | -- | -147.70 | -- | -- | -- | -816.73 | -- | -- | -0.7082 | 0.0048 | -- | -74.64 | -- | -96.36 | -- | -- | -- |
| Ernexa Therapeutics Inc | 535.00k | -46.11m | 14.35m | 6.00 | -- | -- | -- | 26.83 | -93.67 | -93.67 | 0.313 | -1.71 | 0.0196 | -- | 2.11 | 89,166.66 | -168.48 | -187.10 | -252.50 | -237.72 | 93.46 | -- | -8,615.70 | -3,375.91 | -- | -2.31 | -- | -- | 755.88 | -50.61 | -105.47 | -- | -19.54 | -- |
| Neuphoria Therapeutics Inc | -100.00bn | -100.00bn | 14.46m | 8.00 | -- | 0.5484 | -- | -- | -- | -- | -- | 14.02 | -- | -- | -- | -- | -- | -36.91 | -- | -41.62 | -- | -- | -- | -28,341.54 | -- | -- | 0.0012 | -- | -- | -- | 27.54 | -- | -- | -- |
| Hookipa Pharma Inc | 9.35m | -73.31m | 14.51m | 82.00 | -- | 0.4215 | -- | 1.55 | -5.85 | -5.85 | 0.7457 | 2.82 | 0.0903 | -- | 1.74 | 114,036.60 | -70.79 | -40.82 | -91.08 | -50.56 | -- | -- | -784.01 | -266.20 | -- | -- | 0.00 | -- | 118.32 | 29.77 | 46.67 | -- | -37.28 | -- |
| Edesa Biotech Inc | 0.00 | -5.84m | 14.68m | 16.00 | -- | 2.31 | -- | -- | -1.60 | -1.60 | 0.00 | 2.21 | 0.00 | -- | -- | 0.00 | -50.92 | -102.42 | -58.78 | -121.94 | -- | -- | -- | -15,754.49 | -- | -- | 0.00 | -- | -- | -- | 26.32 | -- | -- | -- |
| Kazia Therapeutics Ltd (ADR) | 1.53m | -17.61m | 14.68m | 12.00 | -- | -- | -- | 9.62 | -163.19 | -163.19 | 14.47 | -494.90 | 0.0934 | -- | 34.73 | -- | -107.82 | -56.28 | -328.40 | -73.72 | -- | -- | -1,154.22 | -528.18 | -- | -- | -- | -- | 10,183.69 | 87.68 | -30.85 | -- | -- | -- |
| Raphael Pharmaceutical Inc | 0.00 | -1.40m | 14.72m | 0.00 | -- | -- | -- | -- | -0.0736 | -0.0736 | 0.00 | -0.0374 | 0.00 | -- | -- | -- | -626.91 | -- | -- | -- | -- | -- | -- | -- | -- | -126.09 | -- | -- | -- | -- | -13.02 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Citadel Securities LLCas of 31 Mar 2025 | 11.74k | 0.76% |
| GAMMA Investing LLCas of 31 Mar 2025 | 1.19k | 0.08% |
| Morgan Stanley & Co. LLCas of 31 Mar 2025 | 100.00 | 0.01% |
| RhumbLine Advisers LPas of 31 Mar 2025 | 72.00 | 0.01% |
| SBI Securities Co., Ltd.as of 31 Mar 2025 | 5.00 | 0.00% |
